Please login to the form below

Not currently logged in
Email:
Password:

dermatology

This page shows the latest dermatology news and features for those working in and with pharma, biotech and healthcare.

Novartis gains label boost for Cosentyx

Novartis gains label boost for Cosentyx

We are reimagining the well-being of patients living with all facets of psoriatic arthritis," said Eric Hughes, Global Development Unit Head, Immunology, Hepatology and Dermatology.

Latest news

  • Big Pharma, Little Pharma Big Pharma, Little Pharma

    The company took a big risk when it bought Allergan’s dermatology portfolio.

  • New data keeps AbbVie’s star pipeline therapies on track New data keeps AbbVie’s star pipeline therapies on track

    AbbVie has presented new data on its risankizumab candidate in psoriasis and upadacitinib in atopic dermatitis that suggest it has a potentially lucrative dermatology franchise on the way. ... At the European Academy of Dermatology and Venereology (EADV)

  • Novartis sells off part of Sandoz portfolio Novartis sells off part of Sandoz portfolio

    The move, which will see Sandoz do away with its lower margin segments of US dermatology and generic oral solid portfolios, allows the firm to re-focus its business. ... In return Aurobindo is set to receive approximately 300 products, as well as

  • Realm toppled by second mid-stage trial flop Realm toppled by second mid-stage trial flop

    The company also thinks that its hypochlorous acid formulations could have potential “in immune-mediated diseases generally,” although programmes outside of dermatology are at the very early stages of development.

  • FDA gives breakthrough status to Xolair for food allergies FDA gives breakthrough status to Xolair for food allergies

    Since then Roche and Novartis have built on the drug’s approved uses, expanding its label in allergic asthma and adding a dermatology indication – the treatment of chronic idiopathic urticaria (hives) –

More from news
Approximately 11 fully matching, plus 161 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    in 2018, and includes 300 products, development projects, branded dermatology products and the dermatology development centre and three manufacturing sites in the US. ... Roche. Oral solid generics and dermatology business. Collaboration. $1.375B. Sandoz/

  • Leo has its eyes on the prize Leo has its eyes on the prize

    More than a century has passed since the Nobel Prize in Medicine was awarded for dermatology. ... There are huge unmet needs and the predictions are that the dermatology market will grow significantly over the coming years.

  • Deal Watch January 2018

    Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China).

  • Pharma deals continue to slide Pharma deals continue to slide

    Roche has licensed a monoclonal antibody in phase II to Dermira, a dermatology company.

  • Deal Watch September 2016 Deal Watch September 2016

    The Vitae acquisition builds Allergan's dermatology pipeline with VTP-43742, a mid stage, orally active RORγt (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis,

More from intelligence
Approximately 0 fully matching, plus 35 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 27 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics